Gleason分级与雄激素剥夺治疗时长及生存结局的关联:系统综述与患者水平Meta分析
该研究基于6项随机临床试验992例高危前列腺癌患者的个体数据,采用传统与网络Meta分析,发现GG4患者长期或短期ADT均改善总生存,而GG5患者仅终身ADT改善总生存;GG5患者短期ADT生存劣于GG4。
要点
- GG4患者:长期或短期ADT均改善OS,终身ADT未显示获益。
- GG5患者:仅终身ADT改善OS,长期或短期ADT未显示获益。
- GG5患者接受短期ADT时OS劣于GG4患者。
核心结论
- 延长ADT时长可改善GG4和GG5患者生存,但最佳时长不同:GG4可从长期或短期ADT获益,GG5需终身ADT。
研究设计与样本
- 传统与网络个体患者数据Meta分析,纳入6项随机临床试验共992例患者(GG4 593例,GG5 399例),中位随访6.4年。
主要发现
- GG4患者中,长期ADT对比单纯放疗的OS HR为0.43(95%CI 0.26-0.70),短期ADT对比单纯放疗的OS HR为0.59(95%CI 0.38-0.93)。
- GG4患者中,终身ADT对比单纯放疗的OS HR为0.84(95%CI 0.54-1.30),无显著差异。
- GG5患者中,终身ADT对比单纯放疗的OS HR为0.48(95%CI 0.31-0.76),长期ADT的OS HR为0.80(95%CI 0.45-1.44),短期ADT的OS HR为1.13(95%CI 0.69-1.87)。
- 所有患者中,GG5对比GG4的OS HR为1.25(95%CI 1.07-1.47);接受短期ADT者中,GG5对比GG4的OS HR为1.40(95%CI 1.05-1.88)。
- 接受长期ADT或终身ADT者中,GG5与GG4的OS无显著差异(HR分别为1.21(95%CI 0.89-1.65)和0.85(95%CI 0.53-1.37))。
临床怎么用
- GG4高危前列腺癌接受放疗时,可考虑长期或短期ADT。
- GG5高危前列腺癌接受放疗时,宜推荐终身ADT。
- GG5患者采用短期ADT可能生存劣于GG4,应避免。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Androgen deprivation therapy (ADT) improves survival outcomes in patients with high-risk prostate cancer (PCa) treated with radiotherapy (RT). Whether this benefit differs between patients with Gleason grade group (GG) 4 (formerly Gleason score 8) and GG 5 (formerly Gleason score 9-10) disease remains unknown. OBJECTIVE: To determine whether the effectiveness of ADT duration varies between patients with GG 4 vs GG 5 PCa. DESIGN, SETTING, AND PARTICIPANTS: Traditional and network individual patient data meta-analyses of 992 patients (593 GG 4 and 399 GG 5) who were enrolled in 6 randomized clinical trials were carried out. MAIN OUTCOMES AND MEASURES: Multivariable Cox proportional hazard models were used to obtain hazard ratio (HR) estimates of ADT duration effects on overall survival (OS) and distant metastasis-free survival (DMFS). Cause-specific competing risk models were used to estimate HRs for cancer-specific survival (CSS). The interaction of ADT with GS was incorporated into the multivariable models. Traditional and network meta-analysis frameworks were used to compare outcomes of patients treated with RT alone, short-term ADT (STADT), long-term ADT (LTADT), and lifelong ADT. RESULTS: Five hundred ninety-three male patients (mean age, 70 years; range, 43-88 years) with GG 4 and 399 with GG 5 were identified. Median follow-up was 6.4 years. Among GG 4 patients, LTADT and STADT improved OS over RT alone (HR, 0.43; 95% CI, 0.26-0.70 and HR, 0.59; 95% CI, 0.38-0.93, respectively; P = .03 for both), whereas lifelong ADT did not (HR, 0.84; 95% CI, 0.54-1.30; P = .44). Among GG 5 patients, lifelong ADT improved OS (HR, 0.48; 95% CI, 0.31-0.76; P = .04), whereas neither LTADT nor STADT did (HR, 0.80; 95% CI, 0.45-1.44 and HR, 1.13; 95% CI, 0.69-1.87; P = .45 and P = .64, respectively). Among all patients, and among those receiving STADT, GG 5 patients had inferior OS compared with GG 4 patients (HR, 1.25; 95% CI, 1.07-1.47 and HR, 1.40; 95% CI, 1.05-1.88, respectively; P = .02). There was no significant OS difference between GG 5 and GG 4 patients receiving LTADT or lifelong ADT (HR, 1.21; 95% CI, 0.89-1.65 and HR, 0.85; 95% CI, 0.53-1.37; P = .23 and P = .52, respectively). CONCLUSIONS AND RELEVANCE: These data suggest that prolonged durations of ADT improve survival outcomes in both GG 4 disease and GG 5 disease, albeit with different optimal durations. Strategies to maintain the efficacy of ADT while minimizing its duration (potentially with enhanced potency agents) should be investigated.
引用
- Kishan AU, Wang X, Seiferheld W, et al. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. JAMA Oncol. 2019. PMID: 30326032. doi:10.1001/jamaoncol.2018.3732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。